With the entire world just falling apart and staying in self and/or outwardly induced quarantine, a ray of light has finally shone through. The vaccines for the much dreaded and hated COVID-19 has finally come to the final phases of testing and production.
In the midst of so many updates and news, we here have curated the three most sought after vaccines, namely AstraZeneca, Pfizer and Covaxin.
Let us take a deeper look into each of them to make sure you know everything you need to know as of today.
Oxford-AstraZeneca
Hailing from Cambridge, England, United Kingdom, Oxford and AstraZeneca have merged their forces to produce the vaccine, codenamed “AZD1222”.
The overall efficacy is at 70 per cent, however, while using a regimen of first injecting half a dose of the vaccine and then a full dose a month later, the effectiveness was 90 per cent.
In another system of one full dosage and another a month later, the efficacy stood at 62 per cent. Quite ironic because the second system has more vaccines injected.
Their press release on November 23rd stated that they are targeting 3 billion doses worldwide by the end of 2021.
They want to show their commitment to making the world a better place and are planning to sell it at a cost which is around EUR 2.50 or USD 3.00.
Also Read: Pfizer’s Coronavirus Vaccine Announcement Impacts Zoom; Shares Fall By 16%
Pfizer
Situated on the Eastern Seaboard in New York City, New York, United States of America, this biopharmaceutical company has worked towards their vaccine “BNT162b2”.
Their numbers are off the charts as their primary efficacy shows to be 95 per cent effective against COVID-19.
The press release of their company stated that the company expects to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. However, they have had no comments on pricing.
Former Vice-President and Chief Scientist of the company Dr. Michael Yeadon, however, has said that there is no need for any vaccines to bring the COVID-19 pandemic to an end.
Covaxin
An indigenous alternative, Bharat Biotech is working with the Indian Council of Medical Research (ICMR). It consists of an inactive sample of the virus.
After having successfully conducted Phase 1 and 2 of clinical trials, they have received the green signal from the Drugs Controller General of India (DCGI) to conduct Phase 3 trials on 26,000 people across 25 test centres in India.
Image Source: Google Images
Sources: Pfizer, AstraZeneca, National Herald India
Connect With The Blogger: @shouvonik_bose
This post is tagged under: accurate test for covid, American COVID-19 Vaccine, astrazeneca vaccine, covid 19 impact, covid 19 vaccine india, Pfizer, pfizer zoom shares
Other Recommendations:
How We Need To Identify Internal Threats First In Order To Deal With The External Ones
